SEATTLE, June 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022 at 2:00 p.m. ET in New York, New York.

A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the presentation will be available on the website for 90 days.

About Impel Pharmaceuticals

Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary POD® technology with well-established therapeutics. In addition to Trudhesa® nasal spray, which is approved in the U.S. for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism.

For additional information about Impel, please visit www.ImpelPharma.com 

Contact:

Media Relations:

Melyssa Weible

Elixir Health Public Relations

Phone: (1) 201-723-5805

Email: mweible@elixirhealthpr.com

Investor Relations

Christina Tartaglia

Stern Investor Relations

Phone: 212-362-1200

Email: christina.tartaglia@sternir.com